anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The purpose of this study is to evaluate the efficacy, safety, and adequacy of EUS-guided liver biopsy in patients undergoing EUS-guided liver biopsy at Methodist Dallas Medical Center (MDMC). This is a clinical quality improvement (CQI) initiative to evaluate outcomes within our institution. The data collected will be used to inform new innovative ways to improve EUS-guided liver biopsy with an ultimate goal of improving the quality of patient care. The clinical outcomes of this patient population have not been previously systematically reviewed in MDMC. Currently, the procedure in not being performed routinely at Methodist Dallas Medical Center (MDMC). However, with new technical and physician expertise, this option is now available at our institution. PI will evaluate the efficacy, safety, and adequacy of EUS-guided liver biopsy in patients requiring histologic examination of their liver at MDMC.
PROBLEM TO BE SOLVED: To obtain a new compound having excellent proliferation inhibiting action on vascular smooth muscle cell, etc., and useful as an agent for suppressing the thickening of vascular wall. SOLUTION: This compound is expressed by formula I (R<1> is H, a halogen, OH, an alkyl, an alkoxy, etc.; R<2> and R<3> are each H, a halogen, an alkyl, an alkoxy, etc.; R<4> , R<5> and R<6> are each H, OH, an alkyl, an alkoxy, carnboxyl or an alkoxycarbnonyl; R is H or an alkyl) and its salt, e.g. 1-(3,4,5- trimethxycinnamoyl)-1,2,3,4-tetrahydroquinoline-2-carboxylic acid methyl ester. The compound of formula I can be produced by reacting a cinnamic acid derivative of formula II with a compound of formula III in an inert solvent in the presence or absence of a dehydration agent or a condensation agent and, as necessary, hydrolyzing the ester group.  The compound is effective for preventing the restenosis of coronary artery after PTCA, restenosis after DCA, restenosis after leaving a stent in the vessel, restenosis after the transplantation of self vessel or artificial vessel, arteriosclerosis, etc.
The invention discloses a multifunctional compound micro-ecological preparation for culturing holothurian, which comprises Bacillus atrophaeus, Bacillus subtilis, Bacillus cereus and a carrier. The symbiosis among probiotic bacteria screened by the multifunctional compound microecological preparation for culturing the holothurian is good; the multifunctional compound micro-ecological preparation for culturing the holothurian has a better antagonistic action on the pathogenic bacteria of the holothurian, has the functions of increasing the growth speed, the immunity and the vitality of the digestive enzyme of the intestinal tract of the holothurian and achieves multiple effects of antibiosis, immunity and growth promotion through the compatibility of the probiotic bacteria. Indigenous floras screened from the intestinal tract of the holothurian is safe and nontoxic for the holothurian, has a high breeding speed, is easy to culture, has high environment adaptation and can be faster bred to form predominant bacteria. The application method is simple and convenient, i.e. only the preparation needs to be added to a feed in proportion to be thrown to feed the holothurian. The multifunctional compound microecological preparation for culturing the holothurian is suitable for breeding and culturing young holothurians and controlling the diseases of the holothurian under various culture modes. The multifunctional compound micro-ecological preparation for culturing the holothurian plays an important role in improving the quality of holothurian merchandises and ensuring the food safety.
Tinnitus is the abnormal perception of sound in the absence of a corresponding external acoustic stimulus, which seriously affects the patients' quality of life, physical and mental health, and the safety of life. There is almost no effective cure for tinnitus, primarily due to its complicated etiopathogenesis and unclear mechanisms. As a major and ancient physical therapy in Traditional Chinese Medicine, acupuncture has been widely used in tinnitus because of its simple operation, rapid effect, and low cost. This paper reviews the relevant literature on the treatment of different kinds of tinnitus by acupuncture, and summarizes the therapeutic efficacy and mechanism of acupuncture on tinnitus, which is expected to provide new ideas and research directions for the study of tinnitus treatment by acupuncture. Tinnitus is the abnormal perception of sound in the absence of a corresponding external acoustic stimulus, which seriously affects the patients' quality of life, physical and mental health, and the safety of life. There is almost no effective cure for tinnitus, primarily due to its complicated etiopathogenesis and unclear mechanisms. As a major and ancient physical therapy in Traditional Chinese Medicine, acupuncture has been widely used in tinnitus because of its simple operation, rapid effect, and low cost. This paper reviews the relevant literature on the treatment of different kinds of tinnitus by acupuncture, and summarizes the therapeutic efficacy and mechanism of acupuncture on tinnitus, which is expected to provide new ideas and research directions for the study of tinnitus treatment by acupuncture.
The invention provides traditional Chinese medicine calculus removing capsules, which are prepared from traditional Chinese medicine materials of: christina loosestrife herb, cluster mallow fruit, medicinal cyathula officinalis root, wenchow turmeric root tuber, chicken's gizzard-membrane, rhubarb, Baikal skullcap root, akabia stem, submature bitter orange, tuckahoe, largehead atractylodes rhizome, Chinese taxillus herb, Chinese thorowax root, different leaves pseudostellaria root tuber, white peony root, cattail pollen, trogopterus dung, licorice root, garden radish seed, officinal magnolia bark, nutgrass galingale rhizome, common burreed tuber, and weeping forsythia fruit. The calculus removing capsules provided by the invention has the functions of meridians warming, pain relieving, qinourishing, body fluid promoting, blood nourishing, liver nourishing, heat clearing, detoxifying, stasis removing, qi promoting, and the like. With the calculus removing capsules, calculus moving canbe promoted, and calculus can finally be discharged out of the body. Traditional Chinese medical science contains extensive disease-controlling experiences and theories of the Chinese people, handed down from thousands of years. The calculus removing capsules provided by the invention are composed of Chinese herbal medicines with the functions of inflammation resisting, toxin resisting, diuresis,cholaneresis, spleen strengthening, kidney invigorating, liver protecting, calculus degrading, and calculus removing. As a result of clinical applications, the calculus removing capsules provide unique curative effects against various calculosis.
BACKGROUND: Reduction mammaplasty can provide symptomatic relief to patients suffering from macromastia; however, complications such as dehiscence are common. It is unknown if the presence of complications affects patient-reported outcomes.
OBJECTIVES: The aim of this study was to determine the risk factors for the development of complications, and to examine the correlation between postoperative complications and patient-reported outcomes in reduction mammaplasty.
METHODS: A single-center retrospective chart review was undertaken of patients who received reduction mammaplasties (CPT 19318), performed by 13 surgeons, between January 2017 and February 2023. Breast cancer cases and oncoplastic reconstructions were excluded. Patients with >1 complication were grouped into the complications cohort. Satisfaction was assessed by administering the BREAST-Q survey.
RESULTS: A total of 661 patients were included for analysis, 131 of whom developed at least 1 complication. Patients in the group with complications had significantly higher average ages and BMIs, and a higher likelihood of hypertension and diabetes (P < .01). Among 180 BREAST-Q responders, 41 had at least 1 complication. There were no significant differences between the 2 groups (complications vs no complications) across survey outcomes. Although obese patients were more likely to develop infection and require revisions (P < .01), no significant differences in subgroup analysis of patient-reported outcomes focusing on obese patients were observed.
CONCLUSIONS: Obesity, hypertension, and diabetes were associated with postoperative complications of reduction mammaplasty. Patients with complications had similar postoperative BREAST-Q satisfaction to patients without complications. Although risk optimization is critical, patients and surgeons should be reassured that satisfaction may be achieved even in the event of a complication.
The purpose of this pilot trial is to determine whether hypothermia improves neurological outcome (measured as 3 and 6 months after the onset of symptoms using mRS, GOS and BI) in patients who has suffered a primary intracerebral hemorrhage. The patients with primary intracerebral hemorrhage presented with coma (GCS ≤ 8) and ICH score 2-4 will be included. Induction of hypothermia will be initiated within 6 hours of symptoms onset. Patients will be cooled to core temperature of 34°C during 24 hours using non-invasive temperature management (Cincinnati Sub-Zero). The temperature will be measured continuously by esophageal system. After 24 hours of successful cooling, the target temperature will be gradually raised to achieve slow re-warming of 0.5°C / 2 h until the core temperature reaches 36,5°C.

During hypothermia ECG, blood pressure, oxygen saturation and intracranial pressure will be measured continuously and registered every 30 min. The first CT scan of the brain, after initial, will be done early after normothermia is reached.
A method of producing a virus like particle (VLP) in a plant comprising modified H3 hemagglutinin is provided. The method comprises introducing a nucleic acid comprising a regulatory region active in the plant and operatively linked to a nucleotide sequence encoding a modified influenza hemagglutinin (HA) protein into the plant, or portion of the plant, the modified HA protein comprises a modified proteolytic loop. Followed by incubating the plant or portion of the plant under conditions that permit the expression of the nucleic acids, thereby producing the VLP. The modified proteolytic loop may comprise one or more protease cleavage sites exhibiting reduced or abolished cleavage by a protease. Also described is a virus like particle (VLP) produced by the method, and plants expressing the VLP. The virus like particle (VLP) may comprise plant-specific N-glycans, or modified N-glycans.
BACKGROUND: Decompressive craniectomy (DC), a surgery to remove part of the skull and open the dura mater, maybe an effective treatment for controlling intracranial hypertension. It remains great interest to elucidate whether DC is beneficial to intracerebral hemorrhage (ICH) patients who warrant clot removal (CR) to prevent intracranial hypertension.
METHODS: The trial was a prospective, pragmatic, controlled trial involving adult patients with ICH who were undergoing removal of hematoma. ICH patients were randomly assigned at a 1:1 ratioto undergo CR with or without DC under the monitoring of intracranial pressure. The primary outcome was the proportion of unfavorable functional outcome (modified Rankin Scale 3-6) at 3 months. Secondary outcomes included the mortality at 3 months and the occurrence of reoperation.
RESULTS: A total of 102 patients were assigned to the CR with DC group and 102 to the CR group. Median hematoma volume was 54.0 ml (range 30-80 ml) and median preoperative Glasgow Coma Scale was 10 (range 5-15). At 3 months, 94 patients (92.2%) in CR with DC group and 83 patients (81.4%) in the CR group had unfavorable functional outcome ( P =0.023). Fourteen patients (13.7%) in the CR with DC group died versus five patients (4.9%) in the CR group ( P =0.030). The number of patients with reoperation was similar between the CR with DC group and CR group (5.9 vs. 3.9%; P =0.517). Postoperative intracranial pressure values were not significantly different between two groups and the mean values were less than 20 mmHg.
CONCLUSIONS: CR without DC decreased the rate of modified Rankin Scale score of 3-6 and mortality in patients with ICH, compared with CR with DC.
In group A induction of anesthesia will be performed with Propofol (2mg/kg), Cisatracurium (0.15mg/kg)and continous infusion of Remifentanil (0.15mcg/kg/min).Anesthesia will be maintained by Sevoflurane with oxygen (Fi=40%)and air, with a MAC value to maintain BIS between 40 and 60. Intraoperative analgesia will be obtained with Remifentanil 0.15-0.25mcg/kg/min. Additional boluses of Cisatracurium (0.02mcg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum bolus of morphine (0.1mg/kg)and acetaminophen 1g will be administered. Propofol and remifentanil infusions will be interrupted at the end of wound closure.
After starting amiodarone treatment, cold application was applied a total of 12 times on the infused PVC with cold gel packs for 15 minutes at 2-hour intervals. At all stages of the study, the researcher closely monitored the patients. During the treatment, the development of phlebitis after cold application during the 24-hour infusion was evaluated every 2 hours by the researcher using the "Visual Infusion Phlebitis Scale" and recorded. After starting the amiodarone infusion, the patients were observed for the development of phlebitis for 24 hours until the end of the procedure and for 2 hours after the end of the treatment.
PURPOSE:The titled ointment, containing an ointment base and an indomethacin ester which is a nonsteroidal anti-inflammatory and analgesic agent in a specific proportion, having slight skin irritation by chemical and improved percutaneous absorbability and capable of exhibiting sufficient drug effect without side effects. CONSTITUTION:An anti-inflammatory and analgesic ointment containing 99.7-98.5wt% ointment base, e.g. consisting of dispersing agent selected from polyhydric alcohol esters of fatty acids, polyhydric alcohol adducts of ethylene oxide and sugar esters, etc., viscosity modifiers, e.g. beeswax, and water, and 0.3-1.5wt% indomethacin ester as an active constituent and further preferably a pH adjuster, e.g. malic acid, oxalic acid or lactic acid, for stabilizing the indomethacin and improving the percutaneous absorbability. In production, the oily components are mixed at 80-90 deg.C to give a uniform solution and the indomethacin ester is added thereto. Water and the pH adjuster are mixed to afford the aimed ointment.
Pharmaceutical composition (A) contains at least one mRNA (I), including at least one region that encodes a tumor antigen (Ag), and an aqueous solvent. An independent claim is also included for a method of preparing (A) that comprises: (a) preparing a (partial) cDNA library from tumor tissue; (b) preparing a matrix for in vitro transcription of RNA from the (partial) library; and (c) in vitro transcription of the matrix. ACTIVITY : Cytostatic. Female mice that expressed the rat Her-2/neu oncogene were immunized with mRNA that encoded a truncated form of the Her-2/neu protein (lacking the cytoplasmic regions). Four of ten treated animals were still free of tumors after 9 months; untreated controls had all developed palpable breast tumors after about 20 weeks. MECHANISM OF ACTION : Vaccine.
The prognostic significance of angiogenesis has been demonstrated in various types of cancer. However, in colorectal cancer (CRC), there are conflicting results regarding the relationship between angiogenesis and clinical-histopathological prognostic factors. Mast cells are immune system cells found in the inflammatory microenvironment; their role in carcinogenesis and prognosis remains unclear although they are considered to cause cancer development and progression. The present study aims to evaluate the prognostic significance of mast cell accumulation and angiogenesis assessed by microvessel density (MVD) in patients with CRC. Patients who underwent curative resection and who were not treated with neoadjuvant chemotherapy were included. The anti-CD34 antibody and anti-CD117 antibody were utilized for the immunohistochemical assessment of MVD and the mast cell count (MCC) in the tissue samples, respectively. The relationship between MCC, MVD, survival and clinical-histopathological prognostic factors were evaluated. A total of 94 patients were enrolled to the study. In a median 49-month follow-up, 65 patients (69.1%) died. The 5-year disease-free survival was 61.1% and 31.3% for the group with CD34 < 18.3% and CD34 > 18.3%, respectively (P = .001). The same groups presented 5-year overall survival rates of 77, 1% and 51, 4%, respectively (P, .012). The MVD was found to be associated with the pathological T stage, lymph node metastasis and distant metastasis (P < .05). Although the MCC was positively correlated with MVD, there was no association between the MCC and clinical-histopathological prognostic factors. MVD-assessed angiogenesis was significantly related to survival and the clinical-histopathological prognostic factors in patients diagnosed with CRC.
The AC-058B303 study (extension study) is the long-term extension for the AC-058B301 study (core study). The core study has been designed to investigate the efficacy, safety and tolerability of ponesimod in subjects with RMS. The subjects are treated with either ponesimod or the active comparator, teriflunomide in the core study. The purpose of this long term extension of the core study is to characterize the long-term safety and control of disease of ponesimod in subjects with RMS. In particular, the study will allow to observe potential adverse events which may only occur after long term treatment with ponesimod. The study will also investigate the effect of re-initiation of ponesimod after a brief interruption in a relatively large population (all subjects treated with ponesimod in the core study and eligible for the extension study) on disease activity in terms of relapses and MS-related MRI lesions. There is currently limited guidance on when a new MS treatment should be started after discontinuation of teriflunomide and the study will contribute with data on safety and efficacy of switching from teriflunomide to ponesimod after an interruption as mandated by the protocol. The study will also allow confirmation of sustained efficacy of ponesimod in terms of relapses, MRI lesions and reduction of disability accumulation during long-term treatment. In addition, combined data from the core study together with the results of the current extension study will allow comparison of MS activity in subjects who were switched from teriflunomide to ponesimod versus those who were treated with ponesimod in both studies. A vaccination sub-study will be conducted in a sub-set of up to 50 eligible study participants from selected countries who consent to be vaccinated with the Janssen coronavirus disease-2019 (COVID-19) vaccine (Ad26.COV2.S) to investigate the immune response induced by the Janssen COVID-19 vaccine.
Virus virions defective in F gene are successfully collected by using a Sendai virus genomic cDNA with deletion of F gene. Further, infectious viral particles defective in F gene are successfully constructed by using F-expression cells as helper cells. Also, virus virions defective in F gene and HN gene are successfully collected by using a virus genomic cDNA with deletion of both of F gene and HN gene. Further, infectious viral particles defective in F gene and HN gene are successfully produced by using F- and HN-expression cells as helper cells. A virus being defective in F gene and HN gene and having F protein is constructed by using F-expression cells as helper cells. Further, a VSV-G pseudo type virus is successfully constructed by using VSV-G-expression cells. Techniques for constructing these defective viruses contribute to the development of vectors of Paramyxoviridae usable in gene therapy.
Symptomatic non-stenotic carotid plaques (SyNC) are an under-researched and under-recognized source of stroke. Various imaging markers of non-stenotic carotid plaques that are associated with stroke risk have been identified, but these causal relationships need to be confirmed in additional prospective studies. Currently, there exists neither a standardized SyNC definition nor a dedicated set of imaging protocols, although researchers have started to address these shortcomings. Moreover, many neuroradiologists are still unaware of the condition, and hence do not comment on high-risk plaque features other than stenosis in their reports. Regarding SyNC treatment, scant data exist as to whether and to what extent medical, interventional and surgical treatments could influence the course of the disease; the relative lack of data on the 'natural' history of untreated SyNC makes treatment comparisons difficult. In our opinion, endovascular SyNC treatment represents the most promising treatment option for SyNC, since it allows for targeted elimination of the embolic source, with few systemic side effects and without the need for general anesthesia. However, currently available carotid devices are designed to treat stenotic lesions, and thus are not optimally designed for SyNC. Developing a device specifically tailored to SyNC could be an important step towards establishing endovascular SyNC treatment in clinical practice. In this review, we provide an overview of the current state of evidence with regard to epidemiological, clinical and imaging features of SyNC, propose a SyNC definition based on imaging and clinical features, and outline a possible pathway towards evidence-based SyNC therapies, with a special focus on endovascular SyNC treatment.